Advanced Renal Cell Carcinoma Treatment Global Market Report 2025

The advanced renal cell carcinoma treatment market size has grown strongly in recent years. It will grow from $8.1 billion in 2024 to $8.75 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising geriatric population, an increasing prevalence of smoking, a surge in hypertension cases, higher healthcare expenditure, and a growing number of renal cancer cases.

The advanced renal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $11.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be driven by the increasing incidence of genetic conditions, the rising prevalence of chronic high blood pressure, the adoption of tyrosine kinase inhibitors, greater awareness of kidney cancer, and increased investments in research and development. Key trends include technological advancements in diagnostics, innovations in targeted therapies, the development of oral treatment options, progress in liquid biopsy technology, and the integration of artificial intelligence in drug development.

The increasing prevalence of genetic conditions is expected to drive the growth of the advanced renal cell carcinoma (RCC) treatment market. Genetic conditions are disorders or diseases resulting from DNA abnormalities, which may be inherited from parents or arise due to mutations occurring during an individual’s lifetime. The rising incidence of genetic conditions is attributed to advancements in diagnostic technologies, improved awareness and reporting, as well as environmental and lifestyle factors that interact with genetic predispositions. Advanced renal cell carcinoma (RCC) treatment plays a crucial role in managing genetic conditions by targeting specific molecular pathways, enabling personalized therapies that address the genetic drivers of tumor development and progression. For example, in June 2023, Gene People, a UK-based registered charity, estimated that 1 in 25 children is affected by genetic conditions, with more than 2.4 million individuals in the UK living with a genetic disorder. Additionally, approximately 30,000 newborns and children are diagnosed with genetic conditions annually in the UK. As a result, the increasing prevalence of genetic conditions is fueling the expansion of the advanced renal cell carcinoma (RCC) treatment market.

Leading companies in the advanced renal cell carcinoma (RCC) treatment market are focusing on the development of innovative therapies, such as hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors, to improve treatment effectiveness and patient outcomes. HIF-2α inhibitors are a class of drugs designed to block the activity of HIF-2α, a protein that regulates the body’s response to low oxygen levels. For instance, in December 2023, Merck & Co. Inc., a US-based healthcare company, received U.S. Food and Drug Administration (FDA) approval for WELIREG (belzutifan), an oral HIF-2α inhibitor. This groundbreaking treatment is specifically intended for patients previously treated with PD-1 or PD-L1 inhibitors and VEGF-TKI therapies. The approval is significant as it introduces a novel therapeutic option for a patient population with limited treatment alternatives, offering potential for improved disease management and outcomes in advanced RCC.

In December 2023, Exelixis Inc., a US-based biotechnology company, entered into a partnership with Arcus Biosciences Inc. to accelerate the development of novel cancer therapies. Through this collaboration, Exelixis and Arcus Biosciences aim to advance treatments for advanced renal cell carcinoma and other solid tumors, leveraging the STELLAR-009 clinical trial to drive innovation. Arcus Biosciences Inc. is a US-based biotechnology company specializing in renal cell carcinoma treatment solutions.

Major players in the advanced renal cell carcinoma treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen SA, Exelixis Inc., BeiGene Ltd., Bavarian Nordic A/S, Telix Pharmaceuticals Limited, CRISPR Therapeutics AG, Beijing Scitech-Mq Pharmaceuticals Limited, HUTCHMED (China) Limited, Arcus Biosciences Inc., NGM Biopharmaceuticals Inc., Mirati Therapeutics Inc.

North America was the largest region in the advanced renal cell carcinoma treatment market in 2024. The regions covered in advanced renal cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced renal cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Advanced renal cell carcinoma (RCC) treatment encompasses medical interventions and therapies designed to manage and improve outcomes in later stages of the disease, where the cancer has spread beyond the kidney. These treatments typically include targeted therapies, immunotherapy, and, in some cases, radiation therapy to slow cancer progression and relieve symptoms.

The primary treatment options for advanced renal cell carcinoma (RCC) consist of biologics, radiation therapy, chemotherapy, hormone therapy, vaccine therapy, and other approaches. Biologics, which are derived from living organisms, specifically target cancer cells and boost the immune system, playing a crucial role in advanced RCC treatment. These medications can be administered via different routes, including parenteral, oral, and others. Various healthcare providers, such as hospitals, cancer research institutes, ambulatory surgical centers, and others, utilize these treatments.

The advanced renal cell carcinoma (RCC) treatment market research report is one of a series of new reports that provides advanced renal cell carcinoma (RCC) treatment market statistics, including the advanced renal cell carcinoma (RCC) treatment industry global market size, regional shares, competitors with the advanced renal cell carcinoma (RCC) treatment market share, detailed advanced renal cell carcinoma (RCC) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the advanced renal cell carcinoma (RCC) treatment industry. This advanced renal cell carcinoma (RCC) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The advanced renal cell carcinoma (RCC) treatment market includes revenues earned by entities by providing services such as targeted therapy administration, nephrectomy, medical consultation services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.